analyse_stat_20250418.R

##chargement des packages----
library(questionr)
library(tidyverse)

## ── Attaching core tidyverse packages ──────────────────────── tidyverse 2.0.0 ──
## ✔ dplyr     1.1.1     ✔ readr     2.1.4
## ✔ forcats   1.0.0     ✔ stringr   1.5.0
## ✔ ggplot2   3.4.2     ✔ tibble    3.2.1
## ✔ lubridate 1.9.2     ✔ tidyr     1.3.0
## ✔ purrr     1.0.1     
## ── Conflicts ────────────────────────────────────────── tidyverse_conflicts() ──
## ✖ dplyr::filter() masks stats::filter()
## ✖ dplyr::lag()    masks stats::lag()
## ℹ Use the conflicted package (<http://conflicted.r-lib.org/>) to force all conflicts to become errors

library(tableone)
library(labelled)
library(gtsummary)

## #Uighur

library(GGally)

## Registered S3 method overwritten by 'GGally':
##   method from   
##   +.gg   ggplot2

library(readxl)
library(effects)

## Le chargement a nécessité le package : carData
## lattice theme set by effectsTheme()
## See ?effectsTheme for details.

library(survival)
library(survminer)

## Le chargement a nécessité le package : ggpubr
## 
## Attachement du package : 'survminer'
## 
## L'objet suivant est masqué depuis 'package:survival':
## 
##     myeloma

library(ggplot2)
library(dplyr)
library(knitr)
library(cowplot)

## 
## Attachement du package : 'cowplot'
## 
## L'objet suivant est masqué depuis 'package:ggpubr':
## 
##     get_legend
## 
## L'objet suivant est masqué depuis 'package:lubridate':
## 
##     stamp

##chargement des données
informations <- read_excel("informations.xlsx")

## New names:
## • `Dosage (mg/j)` -> `Dosage (mg/j)...13`
## • `Dosage (mg/j)` -> `Dosage (mg/j)...15`

##tableau descriptif patients ----
tbl_summary(
  informations, include = c("Age", "Sexe", "Maladie",
                           "Mutation", "anticancereux_prescrit","ligne.cat",
                           "comedication","n_comedication" ,"tac"),
  statistic = all_continuous() ~ "{median} [{min} - {max}]",
  digits=all_categorical()~ c(0,1)
)

Characteristic	N = 1251
Age	68 [40 - 88]
Sexe
F	79 (63.2%)
M	46 (36.8%)
Maladie
Adénocarcinome	101 (92.7%)
Adénocarcinome, carcinome neuroendocrine non à petite cellule, non épidermoïde	1 (0.9%)
Cancer épidermoïde	2 (1.8%)
Carcinome non à petites cellules	2 (1.8%)
Thymome	1 (0.9%)
Thymome B3	1 (0.9%)
Tumeurs neuroendocrines digestives et pulmonaires	1 (0.9%)
Unknown	16
Mutation
ALK	26 (21.1%)
ALK/BRAF	1 (0.8%)
Aucune	7 (5.7%)
BRAF	6 (4.9%)
EGFR	55 (44.7%)
EGFR MET	2 (1.6%)
EGFR TP53 PI3CA	2 (1.6%)
HER2	1 (0.8%)
KIF5 B-RET	1 (0.8%)
KRAS	12 (9.8%)
KRAS STK11	1 (0.8%)
MET	2 (1.6%)
RET	1 (0.8%)
ROS	1 (0.8%)
ROS1	5 (4.1%)
Unknown	2
anticancereux_prescrit
Afatinib	5 (4.0%)
Alectinib	7 (5.6%)
Brigatinib	9 (7.2%)
Cabozantinib	3 (2.4%)
Crizotinib	3 (2.4%)
Dabrafénib Trametinib	6 (4.8%)
Evérolimus	6 (4.8%)
Géfitinib	1 (0.8%)
Lenvatinib	1 (0.8%)
Lorlatinib	14 (11.2%)
Lorlatinib Dabrafénib	1 (0.8%)
Mobocertinib	3 (2.4%)
Osimertinib	48 (38.4%)
Osimertinib Crizotinib	2 (1.6%)
Osimertinib Tepotinib	1 (0.8%)
Pralsetinib	1 (0.8%)
Sotorasib	14 (11.2%)
ligne.cat
1	7 (11.9%)
2	17 (28.8%)
3 et plus	35 (59.3%)
Unknown	66
comedication
Non	5 (4.0%)
Oui	120 (96.0%)
n_comedication	6.0 [0.0 - 21.0]
tac
IM	1 (0.8%)
Non	78 (62.4%)
Oui	46 (36.8%)
1 Median [Range]; n (%)

##tableau descriptif activité pharmacie ----
tbl_summary(
  informations, include = c("consultation_initiale", "analyse_pharmaceutique",
                            "cr_analys_pharma_envoye", "delai_consult_pharma", "envoi_evaluable",
                            "oncologue_destinataire_cr","ide_destinataire_cr", "officine_destinataire_cr",
                            "med_t_destinataire_cr", "consult_toxicite"),
  statistic = all_continuous() ~ "{median} [{min} - {max}]",
  digits=all_categorical()~ c(0,1)
)

Characteristic	N = 1251
consultation_initiale
Non	118 (94.4%)
Oui	7 (5.6%)
analyse_pharmaceutique
Non	11 (8.8%)
Oui	114 (91.2%)
cr_analys_pharma_envoye
IM	28 (22.4%)
Non	14 (11.2%)
Oui	83 (66.4%)
delai_consult_pharma	3 [-58 - 725]
Unknown	15
envoi_evaluable
Non	12 (9.6%)
Oui	113 (90.4%)
oncologue_destinataire_cr
IM	38 (30.4%)
Non	14 (11.2%)
Oui	73 (58.4%)
ide_destinataire_cr
IM	38 (30.4%)
Non	25 (20.0%)
Oui	62 (49.6%)
officine_destinataire_cr
IM	38 (30.4%)
Non	77 (61.6%)
Oui	10 (8.0%)
med_t_destinataire_cr
IM	39 (31.2%)
Non	86 (68.8%)
consult_toxicite
Non	60 (48.0%)
Oui	65 (52.0%)
1 n (%); Median [Range]

##Retours des analyses pharmaceutiques 
##chargement des données

analyse_pharma <- read_excel("analyse_pharma.xlsx")

analyse_pharma_eligible<-filter(analyse_pharma, c(eligible=="oui"))

interaction<-filter(analyse_pharma_eligible, c(ligne_ddi==1))

##description des interactions globales
tbl_summary(
  interaction, include = c("interaction_retrouvee", "Proposition_STP", 'intervention_pharmacien'),
  statistic = all_continuous() ~ "{median} [{min} - {max}]",
  digits=all_categorical()~ c(0,1)
)

Characteristic	N = 5071
interaction_retrouvee
Non	9 (1.8%)
Oui	498 (98.2%)
Proposition_STP
Oui	52 (100.0%)
Unknown	455
intervention_pharmacien
Adaptation plan de prise	160 (32.5%)
Arrêt comédication	16 (3.2%)
Modification posologique anticancéreux	7 (1.4%)
Modification posologique comédication	4 (0.8%)
Optimisation en fonction des indications	1 (0.2%)
Substitution comédication	3 (0.6%)
Surveillance renforcée EI	302 (61.3%)
Unknown	14
1 n (%)

##interactions anticancéreux sur comed
atk_comed<-filter(interaction, c(type_interaction=="Anticancéreux sur comédication"))

tbl_summary(
  atk_comed, include = c("risque_interaction", "anticancereux_concerne", "cat_atc"),
  statistic = all_continuous() ~ "{median} [{min} - {max}]",
  digits=all_categorical()~ c(0,1)
)

Characteristic	N = 3371
risque_interaction
Diminution efficacité comédication	203 (60.2%)
Majoration toxicité comédication	91 (27.0%)
Majoration toxicité ou diminution efficacité comed	41 (12.2%)
Potentialisation d'EI	2 (0.6%)
anticancereux_concerne
Afatinib	1 (0.3%)
Alectinib	1 (0.3%)
Alectinib (métabolite actif)	1 (0.3%)
Brigatinib	26 (7.7%)
Cabozantinib	8 (2.4%)
Crizotinib	20 (5.9%)
Dabrafénib	35 (10.4%)
Evérolimus	8 (2.4%)
Lorlatinib	46 (13.6%)
Mobocertinib	7 (2.1%)
Osimertinib	137 (40.7%)
Sotorasib	45 (13.4%)
Tramétinib	2 (0.6%)
cat_atc
Agents acting on the renin	10 (3.0%)
Analgesics	72 (21.4%)
Anesthetics	4 (1.2%)
ANTI-ACNE PREPARATIONS	2 (0.6%)
Antianemic preparations	2 (0.6%)
Antibacterials for systemic use	1 (0.3%)
Antidiarrheals, intestinal antiinflammatory/antiinfective agents	6 (1.8%)
Antiemetics and antinauseants	5 (1.5%)
Antiepileptics	6 (1.8%)
Antigout preparations	3 (0.9%)
Antihistamines for systemic use	1 (0.3%)
Antithrombotic agents	15 (4.5%)
Beta blocking agents	14 (4.2%)
Calcium channel blockers	14 (4.2%)
Cardiac therapy	3 (0.9%)
Corticosteroids for systemic use	33 (9.8%)
Cough and cold preparations	1 (0.3%)
Diuretics	14 (4.2%)
DRUGS FOR ACID RELATED DISORDERS	32 (9.5%)
Drugs for functional gastrointestinal disorders	1 (0.3%)
Drugs for obstructive airway diseases	8 (2.4%)
Drugs used in diabetes	1 (0.3%)
Laxatives	7 (2.1%)
Lipid modifying agents	29 (8.6%)
Psychoanaleptics	14 (4.2%)
Psycholeptics	35 (10.4%)
Urologicals	4 (1.2%)
1 n (%)

#sources interactions
tbl_summary(
  atk_comed, include = c("BCRP", "P-gp", "MATE1", "MRP2", "OAT3", "OATP1", 
                         "OATP1B1", "OATP1B3", "OTC2", "CYP2C8", "CYP2C9", "CYP2C19", 
                         "CYP3A", "absorption"),
  statistic = all_continuous() ~ "{median} [{min} - {max}]",
  digits=all_categorical()~ c(0,1)
)

Characteristic	N = 3371
BCRP
Modéré	1 (0.3%)
Non	308 (91.4%)
Oui	28 (8.3%)
P-gp
Modéré	24 (7.1%)
Non	290 (86.1%)
Oui	23 (6.8%)
MATE1
Non	336 (99.7%)
Oui	1 (0.3%)
MRP2
Non	329 (97.6%)
Oui	8 (2.4%)
OAT3
Non	333 (98.8%)
Oui	4 (1.2%)
OATP1
Non	336 (99.7%)
Oui	1 (0.3%)
OATP1B1
Non	335 (99.4%)
Oui	2 (0.6%)
OATP1B3
Non	333 (98.8%)
Oui	4 (1.2%)
OTC2
Non	336 (99.7%)
Oui	1 (0.3%)
CYP2C8
Non	336 (99.7%)
Oui	1 (0.3%)
CYP2C9
Faible	2 (0.6%)
Non	332 (98.5%)
Oui	3 (0.9%)
CYP2C19
Faible	2 (0.6%)
Non	335 (99.4%)
CYP3A
Faible	135 (40.1%)
Modéré	71 (21.1%)
Non	83 (24.6%)
Oui	48 (14.2%)
absorption
Absorption	2 (0.6%)
Non	335 (99.4%)
1 n (%)

##interactions comed sur atk
comed_atk<-filter(interaction, c(type_interaction=="Comédication sur anticancéreux"))

tbl_summary(
  comed_atk, include = c("risque_interaction", "anticancereux_concerne", "cat_atc"),
  statistic = all_continuous() ~ "{median} [{min} - {max}]",
  digits=all_categorical()~ c(0,1)
)

Characteristic	N = 1421
risque_interaction
Diminution efficacité anticancéreux	34 (25.8%)
Majoration toxicité anticancéreux	96 (72.7%)
Potentialisation d'EI	2 (1.5%)
Unknown	10
anticancereux_concerne
Afatinib	8 (5.6%)
Alectinib	1 (0.7%)
Alectinib + mtb actif	1 (0.7%)
Brigatinib	5 (3.5%)
Cabozantinib	7 (4.9%)
Crizotinib	8 (5.6%)
Dabrafénib	11 (7.7%)
Evérolimus	7 (4.9%)
Lenvatinib	1 (0.7%)
Lorlatinib	6 (4.2%)
Mobocertinib	5 (3.5%)
Osimertinib	61 (43.0%)
Sotorasib	13 (9.2%)
Tramétinib	8 (5.6%)
cat_atc
Agents acting on the renin	14 (9.9%)
Analgesics	2 (1.4%)
Antibacterials for systemic use	2 (1.4%)
Antidiarrheals, intestinal antiinflammatory/antiinfective agents	14 (9.9%)
Antiemetics and antinauseants	1 (0.7%)
Antiepileptics	1 (0.7%)
Antiinflammatory and antirheumatic products	2 (1.4%)
Antithrombotic agents	2 (1.4%)
Antivirals for systemic use	2 (1.4%)
Beta blocking agents	1 (0.7%)
Calcium channel blockers	15 (10.6%)
Cardiac therapy	3 (2.1%)
Corticosteroids for systemic use	1 (0.7%)
Cough and cold preparations	1 (0.7%)
Diuretics	6 (4.2%)
DRUGS FOR ACID RELATED DISORDERS	46 (32.4%)
Drugs for functional gastrointestinal disorders	2 (1.4%)
Lipid modifying agents	8 (5.6%)
Nasal preparations	2 (1.4%)
Other drugs for disorders of the musculo	1 (0.7%)
Pituitary and hypothalamic hormones	1 (0.7%)
Psychoanaleptics	8 (5.6%)
Psycholeptics	3 (2.1%)
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	1 (0.7%)
VASOPROTECTIVES	3 (2.1%)
1 n (%)

#sources interactions
tbl_summary(
  comed_atk, include = c("BCRP", "P-gp", "MATE1", "MRP2", "OAT3", "OATP1", 
                         "OATP1B1", "OATP1B3", "OTC2", "CYP2C8", "CYP2C9", "CYP2C19", 
                         "CYP3A", "absorption"),
  statistic = all_continuous() ~ "{median} [{min} - {max}]",
  digits=all_categorical()~ c(0,1)
)

Characteristic	N = 1421
BCRP
Modéré	1 (0.7%)
Non	100 (70.4%)
Oui	41 (28.9%)
P-gp
Modéré	7 (4.9%)
Non	99 (69.7%)
Oui	36 (25.4%)
MATE1
Non	135 (95.1%)
Oui	7 (4.9%)
MRP2
Non	141 (99.3%)
Oui	1 (0.7%)
OAT3
Non	142 (100.0%)
OATP1
Non	142 (100.0%)
OATP1B1
Non	142 (100.0%)
OATP1B3
Non	142 (100.0%)
OTC2
Non	142 (100.0%)
CYP2C8
Faible	1 (0.7%)
Non	141 (99.3%)
CYP2C9
Modéré	1 (0.7%)
Non	141 (99.3%)
CYP2C19
Non	142 (100.0%)
CYP3A
Faible	7 (4.9%)
Modéré	9 (6.3%)
Non	123 (86.6%)
Oui	2 (1.4%)
Puissant	1 (0.7%)
absorption
Absoption HE	2 (1.4%)
Absorption	17 (12.0%)
Non	109 (76.8%)
pH gastrique	14 (9.9%)
1 n (%)

##interactions comed sur comed

comed_comed<-filter(interaction, c(type_interaction=="Comédication sur comédication"))

tbl_summary(
  comed_comed, include = c("risque_interaction", "anticancereux_concerne", "comedication_concernee"),
  statistic = all_continuous() ~ "{median} [{min} - {max}]",
  digits=all_categorical()~ c(0,1)
)

Characteristic	N = 231
risque_interaction
Diminution efficacité comédication	18 (78.3%)
Majoration toxicité ou diminution efficacité comed	2 (8.7%)
Potentialisation d'EI	3 (13.0%)
anticancereux_concerne
Bisoprolol	1 (14.3%)
Candésartan	1 (14.3%)
Doxycycline	1 (14.3%)
Escitalopram	1 (14.3%)
Formotérol	1 (14.3%)
Insuline	1 (14.3%)
Tramadol	1 (14.3%)
Unknown	16
comedication_concernee
Amiodarone	1 (4.3%)
Bétaxolol	1 (4.3%)
Calcium	1 (4.3%)
CARBOLEVURE	1 (4.3%)
Diosmectite	7 (30.4%)
FERO-GRAD VITAMINE C	1 (4.3%)
GAVISCON	6 (26.1%)
Octreotide	2 (8.7%)
Racécadotril	1 (4.3%)
Siméticone	1 (4.3%)
Zopiclone, bromazépam, hydroxyzine, alprazolam	1 (4.3%)
1 n (%)

#sources interactions
tbl_summary(
  comed_comed, include = c("BCRP", "P-gp", "MATE1", "MRP2", "OAT3", "OATP1", 
                         "OATP1B1", "OATP1B3", "OTC2", "CYP2C8", "CYP2C9", "CYP2C19", 
                         "CYP3A", "absorption"),
  statistic = all_continuous() ~ "{median} [{min} - {max}]",
  digits=all_categorical()~ c(0,1)
)

Characteristic	N = 231
BCRP
Non	23 (100.0%)
P-gp
Non	23 (100.0%)
MATE1
Non	23 (100.0%)
MRP2
Non	23 (100.0%)
OAT3
Non	23 (100.0%)
OATP1
Non	23 (100.0%)
OATP1B1
Non	23 (100.0%)
OATP1B3
Non	23 (100.0%)
OTC2
Non	23 (100.0%)
CYP2C8
Non	23 (100.0%)
CYP2C9
Non	23 (100.0%)
CYP2C19
Non	23 (100.0%)
CYP3A
Non	22 (95.7%)
Oui	1 (4.3%)
absorption
Absorption	17 (73.9%)
Non	6 (26.1%)
1 n (%)

##interactions atk sur atk

atk_atk<-filter(interaction, c(type_interaction=="Anticancéreux sur anticancéreux"))

tbl_summary(
  atk_atk, include = c("risque_interaction", "anticancereux_concerne", "comedication_concernee"),
  statistic = all_continuous() ~ "{median} [{min} - {max}]",
  digits=all_categorical()~ c(0,1)
)

Characteristic	N = 51
risque_interaction
Diminution efficacité anticancéreux	2 (40.0%)
Majoration toxicité anticancéreux	3 (60.0%)
anticancereux_concerne
Crizotinib	1 (20.0%)
Osimertinib	2 (40.0%)
Tépotinib	1 (20.0%)
Tramétinib	1 (20.0%)
comedication_concernee
Crizotinib	1 (20.0%)
Dabrafénib	1 (20.0%)
Osimertinib	2 (40.0%)
Tépotinib	1 (20.0%)
1 n (%)

#sources interactions
tbl_summary(
  atk_atk, include = c("BCRP", "P-gp", "MATE1", "MRP2", "OAT3", "OATP1", 
                           "OATP1B1", "OATP1B3", "OTC2", "CYP2C8", "CYP2C9", "CYP2C19", 
                           "CYP3A", "absorption"),
  statistic = all_continuous() ~ "{median} [{min} - {max}]",
  digits=all_categorical()~ c(0,1)
)

Characteristic	N = 51
BCRP
Non	5 (100.0%)
P-gp
Non	2 (40.0%)
Oui	3 (60.0%)
MATE1
Non	5 (100.0%)
MRP2
Non	5 (100.0%)
OAT3
Non	5 (100.0%)
OATP1
Non	5 (100.0%)
OATP1B1
Non	5 (100.0%)
OATP1B3
Non	5 (100.0%)
OTC2
Non	5 (100.0%)
CYP2C8
Non	5 (100.0%)
CYP2C9
Non	5 (100.0%)
CYP2C19
Non	5 (100.0%)
CYP3A
Faible	1 (20.0%)
Non	2 (40.0%)
Oui	2 (40.0%)
absorption
Non	5 (100.0%)
1 n (%)

#Analyse des interactions avec TAC

##chargement des données 

analyse_tac <- read_excel("analyse_tac.xlsx")

###descriptif 
tbl_summary(
  analyse_tac, include = c("type_traitement","intervention_pharmacien","nom"),
  statistic = all_continuous() ~ "{median} [{min} - {max}]",
  digits=all_categorical()~ c(0,1)
)

Characteristic	N = 2351
type_traitement
Alimentation	10 (4.3%)
Apithérapie	4 (1.7%)
Aromathérapie	9 (3.8%)
Aucun	83 (35.5%)
Complément alimentaire	84 (35.9%)
Dispositif médical	1 (0.4%)
Elixir	1 (0.4%)
Gemmothérapie	1 (0.4%)
Homéopathie	37 (15.8%)
Mycothérapie	2 (0.9%)
Phytothérapie	2 (0.9%)
Unknown	1
intervention_pharmacien
Absence d'interaction	1 (0.9%)
Contre-indiquée si porteur de PAC	1 (0.9%)
Déconseillée	76 (71.0%)
Déconseillée en gélule	1 (0.9%)
Ok	24 (22.4%)
Prise à 2h de distance	4 (3.7%)
Unknown	128
nom
100% FPP (extrait fermenté de papaye) de IMMUNE’AGE	1 (0.7%)
ACEROLA C-max	1 (0.7%)
Aceticum acidum 15CH	1 (0.7%)
Ail de LA ROYALE	1 (0.7%)
ALVITYL	1 (0.7%)
ALVITYL Vitalité	1 (0.7%)
ANACAPS	1 (0.7%)
Apis 15CH	1 (0.7%)
Apis mellifica 8DH, Aurum muriaticum natronatum 7DH, Avena Sativa 4DH, Hypericum Perforatum 4DH, Ignatia amara 5DH, Phosphoricum acidum 5DH	1 (0.7%)
Aragonite D1 50%, calcarea carb D4 25%, quercus D3	1 (0.7%)
Argile par voie orale	2 (1.3%)
Armoise	1 (0.7%)
Artémisia Annua de HERBAL D-TOX	1 (0.7%)
ARTERIA	1 (0.7%)
Ashwagandha	1 (0.7%)
BERBERIS RADIX D3, CARDUS MARIANUS D2, CHELIDONIUM RADIX D3, COLCHICUM D2, CURCUMA D2, SULFUR D8, TARAXACUM STANNO CULTUM D3	1 (0.7%)
BERROCA	2 (1.3%)
BIBHITAKI FRUIT	1 (0.7%)
BION Vitalité	1 (0.7%)
BIOTIC P7	1 (0.7%)
BIOTICS 3B-G (vitamine B)	1 (0.7%)
Bovista gigantea 5CH	1 (0.7%)
BROMELAINE	1 (0.7%)
Charbon végétal activé	1 (0.7%)
Chelidonium D1, Curcuma D1, Taraxacum stanno cultum D3	1 (0.7%)
China 9CH	1 (0.7%)
Chlorella + Spiruline de Biotona	1 (0.7%)
Chlorure de magnésium et vitamine B6	2 (1.3%)
CHRYSANTELLUM	1 (0.7%)
Compléments alimentaires	1 (0.7%)
CORIOLUS VERSICOLOR EXTRAKT	1 (0.7%)
Corrosol	1 (0.7%)
Cuprum metallicum 9CH	1 (0.7%)
Curcuma + poivre noir de LA ROYALE	1 (0.7%)
D-Mulsion FORTE (vitamine D) de BIOTICS RESEARCH	1 (0.7%)
D3 PROTECT (vitamine D3)	1 (0.7%)
Desmodium	2 (1.3%)
Dilution 5, 7 et 9CH	1 (0.7%)
Epices, thés, infusions, graines…	1 (0.7%)
EPS desmodium	1 (0.7%)
EPS rhodiole et mélisse	1 (0.7%)
ERGY D (Vit D)	2 (1.3%)
ERGYMAG (Mg + zn)	1 (0.7%)
ERGYMAG (Mg + Zn)	1 (0.7%)
ERGYSIL (ortie, silicium, sélénium)	1 (0.7%)
Ferments lactiques des laboratoire Dieti Natura	1 (0.7%)
Ferrum metallicum 7 CH	1 (0.7%)
Ferrum sid D10, Phosphorus D8, Silicea D12 W788 60cc dilution	1 (0.7%)
Fleurs de Bach	1 (0.7%)
FLEXOFYTOL (curcuma)	1 (0.7%)
Floracare XL (bifidobactéries et des lactobacilles) de BIOTICS RESEARCH	1 (0.7%)
Gelée royale	1 (0.7%)
Glutathion	1 (0.7%)
Glutathion Liposomé + de HOD	1 (0.7%)
Graine de plantain	1 (0.7%)
HAIR VOLUME	1 (0.7%)
Huile essentielle de ravintsara	1 (0.7%)
Huile essentielle de Romarin à verbénone	1 (0.7%)
Huile essentielle de Tea tree	1 (0.7%)
Huile essentielle de thym	1 (0.7%)
Huile végétale de millepertuis	2 (1.3%)
Huile végétale de rose musquée	1 (0.7%)
Huille essentielle d'helichryse	1 (0.7%)
Huille essentielle de lavandin	1 (0.7%)
IMMUN ACTIFS	1 (0.7%)
Influenzinum 15CH	1 (0.7%)
INTENZYME FORTE	1 (0.7%)
KIDNEY CLEANSE	1 (0.7%)
KLARELINE	1 (0.7%)
Lachesis 9CH, phosphorus 9CH, nux vomica 9CH	1 (0.7%)
LACTIBIANE REFERENCE	1 (0.7%)
LENODIAR	1 (0.7%)
Levure de riz rouge, oméga 3 et CoQ10	1 (0.7%)
Lithothamne de LA ROYALE	1 (0.7%)
Lycopodium clavatum 15CH	1 (0.7%)
Lycopodium clavatum D10	1 (0.7%)
Macérat de gui de LA ROYALE	1 (0.7%)
MAGN ACTIFS	2 (1.3%)
Maitake	1 (0.7%)
Medulo D8	1 (0.7%)
Mélisse en gélules ou tisanes	1 (0.7%)
MENO ACTIFS	1 (0.7%)
Miel, propolis	1 (0.7%)
Natrum muriaticum 15 CH	1 (0.7%)
Natrum sulfuricum 15CH	1 (0.7%)
Nux vomica 9CH	1 (0.7%)
Oméga 3	1 (0.7%)
OMEGA 3 de Solgar	1 (0.7%)
OMEGABIANE DHA	1 (0.7%)
OPTIFLOR	1 (0.7%)
Phosphorus 30CH	1 (0.7%)
Plumbum mellitum D12 30g Trit	1 (0.7%)
Pollen de fleurs	1 (0.7%)
Pollen en pelotes Bio Miel Besacier	1 (0.7%)
PROCARTIL (glucosamine, chondrotoïne, manganèse, cuivre)	1 (0.7%)
PROPOMAX (propolis verte et brune bio, bioflavonoides et artepilline c)	1 (0.7%)
Prostate 8DH	2 (1.3%)
Psyllium	1 (0.7%)
RENFORSTIM	1 (0.7%)
Ribes nigrum 1DH	1 (0.7%)
Ruscus aculeatus 4DH	1 (0.7%)
Selenium ACE Optimum 50+	1 (0.7%)
SEREMAG (magnésium, taurine et vitamine B6)	1 (0.7%)
Serum de Yersin 9 CH	1 (0.7%)
Sève de bouleau 1DH	1 (0.7%)
STRESS’O (rhadiola, choline, lavande vrai) de PHYSIOSENS	1 (0.7%)
Sulfate de magnésium	1 (0.7%)
Sulfurum 7CH	1 (0.7%)
Teinture mère de Calendula	2 (1.3%)
Teinture mère de Dionaea Muscipula	1 (0.7%)
Teinture mère GINKGO BILOBA	1 (0.7%)
TEMPORAL (Levure de riz rouge, policaosanol, CoQ10)	1 (0.7%)
Thé au citron ou orange-canelle	1 (0.7%)
Thymuline 4CH	1 (0.7%)
THYROSTIM (L-thyroxine, vit C, vit D, zinc…) de Copmed	1 (0.7%)
Tisane	1 (0.7%)
Tisane d’olivier et d’hibiscus	1 (0.7%)
Tisane de thym et sauge	2 (1.3%)
Tisane verveine	1 (0.7%)
Tuberculinum 15CH	1 (0.7%)
UNIBIANE HCA (garcinia)	1 (0.7%)
UNIBIANE R-α lipoïque	1 (0.7%)
Vitamine B12	1 (0.7%)
Vitamine C	2 (1.3%)
VITAMINE C 1000 mg	1 (0.7%)
Vitamine C liposomale de Biocyte	1 (0.7%)
Vitamine C liposomale de LA ROYALE	1 (0.7%)
Vitamine D	1 (0.7%)
VITAMINE D3	1 (0.7%)
Vitamine d3 + k2 de Sunday Naturel	1 (0.7%)
VITAMINE D3 2000UI	1 (0.7%)
VITAMINE D3 800UI de Sante verte	1 (0.7%)
Vitamine K2	1 (0.7%)
VITAMINE K2	1 (0.7%)
Weleda c692	1 (0.7%)
Weleda c720	1 (0.7%)
Zinc	3 (2.0%)
Zinc (amino chelate)	1 (0.7%)
Unknown	84
1 n (%)

#Consultations de toxicités

ct_classes <- read_excel("ct_classes.xlsx")

tbl_summary(
  ct_classes, include = c("tox_digestive","tox_cutanee", "tox_muqueuse",
                          "tox_cardiovasc", "tox_ophtalmo",
                          "tox_pulmonaire", "tox_generale", 
                          "tox_hemato", "tox_musculo_squeletique", 
                          "tox_uro_nephro", "tox_hepatique", 
                          "tox_neuro", "tox_psy", "tox_bio"),
  statistic = all_continuous() ~ "{median} [{min} - {max}]",
  by="medicament",
  digits=all_categorical()~ c(0,1)
)

Characteristic	Afatinib, N = 51	Alectinib, N = 51	Brigatinib, N = 71	Cabozantinib, N = 21	Crizotinib, N = 21	Dabrafénib/Trametinib, N = 21	Evérolimus, N = 51	Lenvatinib, N = 11	Lorlatinib, N = 61	Mobocertinib, N = 21	Osimertinib, N = 261	Osimertinib/Crizotinib, N = 11	Sotorasib, N = 51
tox_digestive	5 (100.0%)	3 (60.0%)	0 (0.0%)	1 (50.0%)	2 (100.0%)	1 (50.0%)	2 (40.0%)	1 (100.0%)	2 (33.3%)	2 (100.0%)	17 (65.4%)	1 (100.0%)	4 (80.0%)
tox_cutanee	4 (80.0%)	2 (40.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	1 (20.0%)	0 (0.0%)	1 (16.7%)	2 (100.0%)	16 (61.5%)	0 (0.0%)	3 (60.0%)
tox_muqueuse	4 (80.0%)	1 (20.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (16.7%)	1 (50.0%)	8 (30.8%)	0 (0.0%)	0 (0.0%)
tox_cardiovasc	0 (0.0%)	3 (60.0%)	1 (14.3%)	2 (100.0%)	1 (50.0%)	1 (50.0%)	2 (40.0%)	1 (100.0%)	2 (33.3%)	0 (0.0%)	2 (7.7%)	0 (0.0%)	0 (0.0%)
tox_ophtalmo	2 (40.0%)	1 (20.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	2 (7.7%)	0 (0.0%)	0 (0.0%)
tox_pulmonaire	0 (0.0%)	3 (60.0%)	3 (42.9%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (16.7%)	0 (0.0%)	3 (11.5%)	0 (0.0%)	2 (40.0%)
tox_generale	3 (60.0%)	1 (20.0%)	2 (28.6%)	1 (50.0%)	1 (50.0%)	0 (0.0%)	3 (60.0%)	0 (0.0%)	1 (16.7%)	2 (100.0%)	9 (34.6%)	0 (0.0%)	3 (60.0%)
tox_hemato	1 (20.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (15.4%)	0 (0.0%)	1 (20.0%)
tox_musculo_squeletique	2 (40.0%)	4 (80.0%)	2 (28.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (100.0%)	3 (50.0%)	0 (0.0%)	7 (26.9%)	0 (0.0%)	3 (60.0%)
tox_uro_nephro	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (20.0%)	1 (100.0%)	0 (0.0%)	0 (0.0%)	1 (3.8%)	0 (0.0%)	1 (20.0%)
tox_hepatique	0 (0.0%)	0 (0.0%)	2 (28.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (16.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
tox_neuro	2 (40.0%)	0 (0.0%)	3 (42.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (11.5%)	0 (0.0%)	3 (60.0%)
tox_psy	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (50.0%)	0 (0.0%)	1 (20.0%)	0 (0.0%)	2 (33.3%)	1 (50.0%)	0 (0.0%)	0 (0.0%)	1 (20.0%)
tox_bio	0 (0.0%)	3 (60.0%)	2 (28.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (20.0%)	0 (0.0%)	1 (16.7%)	0 (0.0%)	1 (3.8%)	0 (0.0%)	0 (0.0%)
1 n (%)